ClinicalTrials.gg
CompletedNCT01938625Updated Nov 21, 2018Results posted

A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation

A Phase 2 interventional study of Simeprevir and Daclatasvir in Hepatitis C, Chronic, sponsored by Janssen R&D Ireland. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-21.

Sponsored by Janssen R&D Ireland (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing simeprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C, Chronic.

Enrollment
18th of 21
35 · median 93
Started
2013
with 4 others
Phase 2
9 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
3 of 21
Janssen R&D Ireland

Among the 21 studies testing simeprevir in Hepatitis C, Chronic, this one is the 18th largest by enrollment, is one of 5 that started in 2013, is one of 9 in phase 2, and was the 11th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 21 studies testing simeprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About simeprevir

Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing simeprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of the study is to evaluate effect of steady-state (when the amount of drug administered (in a given time period is equal to the amount of drug eliminated in that same period) of simeprevir and daclatasvir on the steady-state pharmacokinetics (what a medication does to the body) of cyclosporine (applicable to Part 1 only) and tacrolimus when administered as a combinational regimen in post-orthotopic liver transplantation (OLT) participants with recurrent hepatitis C virus (HCV) genotype 1b infection and effectiveness of a 24-week treatment regimen containing simeprevir, daclatasvir, and ribavirin (RBV) with respect to the proportion of HCV genotype 1b infected post-OLT participants achieving sustained virologic response 12 weeks after end of treatment.

Read the detailed description

This is an open-label (all participants of this study know the identity of the intervention) and multicenter (study conducted at multiple sites) study. This study will be conducted in 2 parts. Both the parts of the study will consist of screening phase (4 weeks), treatment period (24 weeks), and a post-treatment follow-up (24 weeks). A total of 30 participants will be enrolled in Part 1 and Part 2 of the study. A minimum of 9 participants were planned to receive cyclosporine as stable immunosuppressant therapy and a minimum of 9 participants were planned to receive tacrolimus as stable immunosuppressant therapy during Part 1. All participants will be receiving tacrolimus as stable immunosuppressant therapy during Part 2. In Part 1 of the study, participants with Metavir score of F1-F2, will receive a combination of study drugs - simeprevir, daclatasvir, and ribavirin for 24 weeks. In Part 2 of the study, participants with Metavir score F1-F4 will receive a dosing regimen of study drugs based on the data from Part 1 of the study. Safety evaluations will include assessments of adverse events, clinical laboratory tests, urinalysis, electrocardiogram, vital signs, and physical examination. The total study duration for each participant will be approximately 52 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • Hepatitis C, Chronic
  • Recurrent Chronic Hepatitis C
  • Pharmacokinetics
  • Simeprevir
  • Daclatasvir
  • Ribavirin
  • Orthotopic Liver Transplantation
  • TMC435
  • BMS-790052
  • RBV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver transplant between 6 months and 10 years prior to the screening visit
  • virus (HCV) genotype 1 subtype b infection confirmed at screening
  • Screening HCV ribonucleic acid level greater than 10,000 IU/mL
  • HCV treatment-naïve participants must not have received post orthotopic liver transplant treatment with any approved or drug for the treatment of HCV
  • Receiving stable therapy (ie, no change in dose in the last month) with cyclosporine (only allowed in Part 1) or tacrolimus for more than 3 months prior to the screening visit

Exclusion criteria

Exclusion Criteria:

  • Evidence of acute or chronic hepatic decompensation after the liver transplantation (including ascites, bleeding varices or hepatic encephalopathy)
  • Any liver disease of non- etiology, including current evidence of graft rejection except the presence of liver steatosis
  • Any other disease that in the opinion of the investigator would be exacerbated by the known effects of ribavirin
  • Coinfection with HCV of another genotype than genotype 1b, type 1 or 2 (positive HIV-1 or HIV-2 antibodies test at screening), and virus (hepatitis B surface antigen positive)
  • Multi-organ transplant that included heart, lung, pancreas, or kidney
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Part 1

    Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.

    Drug: Simeprevir · Drug: Daclatasvir · Drug: Ribavirin · Drug: Cyclosporine · Drug: Tacrolimus

  • Experimental
    Part 2

    Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.

    Drug: Simeprevir · Drug: Daclatasvir · Drug: Ribavirin · Drug: Tacrolimus

Interventions

  • Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.

  • Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.

  • Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.

  • Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.

  • Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)

    Participants were considered to have achieved SVR12 if hepatitis C virus ribonucleic acid (HCV RNA) levels were less than (\<) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after the end of treatment.

    Time frame: Week 36

Secondary outcomes

  1. Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)

    Participants were considered to have achieved SVR4 if HCV RNA levels were (\<) 25 IU/mL detectable or undetectable at 4 weeks after the end of treatment.

    Time frame: Week 28

  2. Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)

    Participants were considered to have achieved SVR 24 if hepatitis C virus ribonucleic acid (HCV RNA) levels were (\<) 25 IU/mL detectable or undetectable at 24 weeks after the end of treatment.

    Time frame: Week 48

  3. Percentage of Participants With HCV RNA (< 25 IU/mL Undetectable) and HCV RNA < 25 IU/mL Detectable

    Percentage of participants with detectable and undetectable HCV RNA (\<) 25 IU/mL during treatment at Weeks 2,4, 12, and 24 were reported.

    Time frame: Weeks 2, 4, 12, and 24

  4. Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4

    Percentage of participants with HCV RNA (\<) 100 IU/mL at week 4 were reported.

    Time frame: Week 4

  5. Number of Participants With On-Treatment Failure

    On-treatment failure is defined as participants who did not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of treatment. This was to include participants with: 1) Viral breakthrough, defined as a confirmed increase of greater than (\>)1 log10 in HCV RNA from nadir, or confirmed HCV RNA of \>100 IU/mL in participants whose HCV RNA had previously been \<lower limit of quantification (LLOQ) while on treatment; 2) Other with confirmed detectable HCV RNA at the actual end of treatment (example, completed, discontinued due to adverse events (AEs), withdrawal of consent).

    Time frame: Up to Week 24 after actual EOT (week 24)

  6. Number of Participants With Viral Breakthrough

    Viral breakthrough is defined as a confirmed increase of \>1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of \>100 IU/mL in participants whose HCV RNA levels had previously been below the limit of quantification (\<25 IU/mL detectable) or undetectable (\<25 IU/mL undetectable) while on study treatment.

    Time frame: Up to week 24

  7. Number of Participants With Viral Relapse

    Participants who did not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (\>=) LLOQ during follow-up.

    Time frame: Up to Week 24 after actual EOT (week 24)

07

Results

Posted Nov 21, 2018

Participant flow

Participant flow — Overall Study
MilestoneCyclosporineTacrolimus
Started1025
Completed1023
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Adverse event01

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)

Participants were considered to have achieved SVR12 if hepatitis C virus ribonucleic acid (HCV RNA) levels were less than (\<) 25 international unit per milliliter (IU/mL) detectable or undetectable at 12 weeks after the end of treatment.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)
percentage of participantsCyclosporineTacrolimus
Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)100 (69.2 to 100)88 (68.8 to 97.5)
SecondaryPercentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)

Participants were considered to have achieved SVR4 if HCV RNA levels were (\<) 25 IU/mL detectable or undetectable at 4 weeks after the end of treatment.

Time frame:
Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)
percentage of participantsCyclosporineTacrolimus
Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)100 (69.2 to 100)88 (68.8 to 97.5)
SecondaryPercentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)

Participants were considered to have achieved SVR 24 if hepatitis C virus ribonucleic acid (HCV RNA) levels were (\<) 25 IU/mL detectable or undetectable at 24 weeks after the end of treatment.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)
percentage of participantsCyclosporineTacrolimus
Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)100 (69.2 to 100)88 (68.8 to 97.5)
SecondaryPercentage of Participants With HCV RNA (< 25 IU/mL Undetectable) and HCV RNA < 25 IU/mL Detectable

Percentage of participants with detectable and undetectable HCV RNA (\<) 25 IU/mL during treatment at Weeks 2,4, 12, and 24 were reported.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA (< 25 IU/mL Undetectable) and HCV RNA < 25 IU/mL Detectable
percentage of participantsCyclosporineTacrolimus
Week 2: <25 IU/mL detectable3036
Week 2: <25 IU/mL undetectable1012
Week 4: <25 IU/mL detectable3024
Week 4: <25 IU/mL undetectable7068
Week 12: <25 IU/mL detectable00
Week 12: <25 IU/mL undetectable10096
Week 24: <25 IU/mL detectable00
Week 24: <25 IU/mL undetectable100100
SecondaryPercentage of Participants With HCV RNA (<) 100 IU/mL at Week 4

Percentage of participants with HCV RNA (\<) 100 IU/mL at week 4 were reported.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4
percentage of participantsCyclosporineTacrolimus
Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4100100
SecondaryNumber of Participants With On-Treatment Failure

On-treatment failure is defined as participants who did not achieve SVR12 and with confirmed detectable HCV RNA at the actual end of treatment. This was to include participants with: 1) Viral breakthrough, defined as a confirmed increase of greater than (\>)1 log10 in HCV RNA from nadir, or confirmed HCV RNA of \>100 IU/mL in participants whose HCV RNA had previously been \<lower limit of quantification (LLOQ) while on treatment; 2) Other with confirmed detectable HCV RNA at the actual end of treatment (example, completed, discontinued due to adverse events (AEs), withdrawal of consent).

Time frame:
Up to Week 24 after actual EOT (week 24)
Reported as:
Number · participants
Number of Participants With On-Treatment Failure
participantsCyclosporineTacrolimus
Number of Participants With On-Treatment Failure03
SecondaryNumber of Participants With Viral Breakthrough

Viral breakthrough is defined as a confirmed increase of \>1 log10 IU/mL in HCV RNA level from the lowest level reached, or a confirmed HCV RNA level of \>100 IU/mL in participants whose HCV RNA levels had previously been below the limit of quantification (\<25 IU/mL detectable) or undetectable (\<25 IU/mL undetectable) while on study treatment.

Time frame:
Up to week 24
Reported as:
Number · participants
Number of Participants With Viral Breakthrough
participantsCyclosporineTacrolimus
Number of Participants With Viral Breakthrough03
SecondaryNumber of Participants With Viral Relapse

Participants who did not achieve SVR12, with undetectable HCV RNA at the actual end of study drug treatment and confirmed HCV RNA greater than or equal to (\>=) LLOQ during follow-up.

Time frame:
Up to Week 24 after actual EOT (week 24)
Reported as:
Number · participants
Number of Participants With Viral Relapse
participantsCyclosporineTacrolimus
Number of Participants With Viral Relapse00

Adverse events

Collected over Up to 52 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine—4/10 (40%)10/10 (100%)
Tacrolimus—4/25 (16%)23/25 (92%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCyclosporineTacrolimus
PyrexiaGeneral disorders3/100/25
DiarrhoeaGastrointestinal disorders1/100/25
Escherichia Urinary Tract InfectionInfections and infestations1/100/25
Genital HerpesInfections and infestations1/100/25
Facial Bones FractureInjury, poisoning and procedural complications1/100/25
SyncopeNervous system disorders1/100/25
Acute Kidney InjuryRenal and urinary disorders1/100/25
Renal ImpairmentRenal and urinary disorders1/100/25
ProstatitisReproductive system and breast disorders1/100/25
DyspnoeaRespiratory, thoracic and mediastinal disorders1/100/25
Most frequent other events
Showing 10 of 52
Most frequent other events
EventCyclosporineTacrolimus
AnaemiaBlood and lymphatic system disorders7/1011/25
AstheniaGeneral disorders5/107/25
FatigueGeneral disorders2/101/25
HyperbilirubinaemiaHepatobiliary disorders2/102/25
CoughRespiratory, thoracic and mediastinal disorders2/103/25
DyspnoeaRespiratory, thoracic and mediastinal disorders2/101/25
PruritusSkin and subcutaneous tissue disorders1/105/25
HeadacheNervous system disorders1/104/25
VertigoEar and labyrinth disorders0/103/25
DiarrhoeaGastrointestinal disorders1/103/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)CyclosporineTacrolimusTotal
Median64.5 (52 to 69)61 (27 to 69)62 (27 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)CyclosporineTacrolimusTotal
Female4913
Male61622
Region of Enrollment
Region of Enrollment(Participants)CyclosporineTacrolimusTotal
Germany167
Spain3912
Poland077
Italy639
08

Study locations

6 sites
  • Essen, Germany
  • Hamburg, Germany
  • Warszawa, Poland
  • Barcelona, Spain
  • Madrid, Spain
  • Valencia, Spain
09

References and documents

Publications

  • Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, Fagiuoli S, Cieciura T, Durlik M, Calleja JL, Marino Z, Shukla U, Verbinnen T, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, Janssen K, Kalmeijer R, Jessner W. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12696. Epub 2017 May 4. PubMed 28295849 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Apr 2015, 16 months.

Results were first posted in Nov 2018, 3 years 6 months after primary completion. A results delay was requested in Apr 2016.

Of 28 industry-sponsored phase 2 interventional studies under Hepatitis C, Chronic, half reached primary completion within 16 months of starting (the median); a quarter within 10 and three quarters within 28. This study's 16 months is close to that.

Counting every sponsor, half of 35 studies reached it within 17 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2013
First posted
Sep 10, 2013
StartActual
Dec 12, 2013
Primary completionActual
Apr 27, 2015
CompletionActual
Jul 28, 2015
Results delay requested
Apr 5, 2016
Results first posted
Nov 21, 2018
Last update
Nov 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01938625
Responsible party
Sponsor
First posted
Sep 10, 2013
Start date
Dec 12, 2013
Primary completion
Apr 27, 2015
Completion
Jul 28, 2015
Results posted
Nov 21, 2018
Last update
Nov 21, 2018

Study contacts

Janssen R&D Ireland Clinical Trial
study director · Janssen R&D Ireland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simeprevir · Daclatasvir · Ribavirin

Start the discussion